Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many

被引:177
作者
Cadogan, Cathal A. [1 ,2 ]
Ryan, Cristin [1 ,2 ]
Hughes, Carmel M. [1 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland
[2] Royal Coll Surgeons Ireland, RCSI Sch Pharm, Ardilaun House,Block B,111 St Stephens Green, Dublin 2, Ireland
关键词
MEDICATION REGIMEN COMPLEXITY; DRUG-DRUG INTERACTIONS; OLDER-PEOPLE; ELDERLY-PEOPLE; COST OUTCOMES; ADULTS; CARE; HOSPITALIZATION; CONSEQUENCES; VALIDATION;
D O I
10.1007/s40264-015-0378-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The use of multiple medicines (polypharmacy) is increasingly common in middle-aged and older populations. Ensuring the correct balance between the prescribing of 'many' drugs and 'too many' drugs is a significant challenge. Clinicians are tasked with ensuring that patients receive the most appropriate combinations of medications based on the best available evidence, and that medication use is optimised according to patients' clinical needs (appropriate polypharmacy). Historically, polypharmacy has been viewed negatively because of the associated medication safety risks, such as drug interactions and adverse drug events. More recently, polypharmacy has been identified as a risk factor for under-prescribing, such that patients do not receive necessary medications and this can also pose risks to patients' safety and well-being. The negative connotations that have long been associated with the term polypharmacy could potentially be acting as a driving factor for under-prescribing, whereby clinicians are reluctant to prescribe necessary medicines for patients who are already receiving 'many' medicines. It is now recognised that the prescribing of 'many' medicines can be entirely appropriate in patients with several chronic conditions and that the risks of adverse drug events that have been associated with polypharmacy may be greatly reduced when patients' clinical context is taken into consideration. In this article, we outline the current perspectives on polypharmacy and make the case for adopting the term 'appropriate polypharmacy' in differentiating between the prescribing of 'many' drugs and 'too many' drugs. We also outline the inherent challenges in doing so and provide recommendations for future clinical practice and research.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 53 条
  • [1] Primary Care Medication Safety Surveillance with Integrated Primary and Secondary Care Electronic Health Records: A Cross-Sectional Study
    Akbarov, Artur
    Kontopantelis, Evangelos
    Sperrin, Matthew
    Stocks, Susan J.
    Williams, Richard
    Rodgers, Sarah
    Avery, Anthony
    Buchan, Iain
    Ashcroft, Darren M.
    [J]. DRUG SAFETY, 2015, 38 (07) : 671 - 682
  • [2] [Anonymous], 2015, POL GUID
  • [3] [Anonymous], POL MED OPT MAK IT S
  • [4] Cardiovascular polypharmacy is not associated with unplanned hospitalisation: evidence from a retrospective cohort study
    Appleton, Sarah C.
    Abel, Gary A.
    Payne, Rupert A.
    [J]. BMC FAMILY PRACTICE, 2014, 15
  • [5] In defence of polypharmacy
    Aronson, JK
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) : 119 - 120
  • [6] Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
    Barnett, Karen
    Mercer, Stewart W.
    Norbury, Michael
    Watt, Graham
    Wyke, Sally
    Guthrie, Bruce
    [J]. LANCET, 2012, 380 (9836) : 37 - 43
  • [7] Number of drugs in the medication list as an indicator of prescribing quality: a validation study of polypharmacy indicators in older hip fracture patients
    Belfrage, Bjorn
    Koldestam, Anders
    Sjoberg, Christina
    Wallerstedt, Susanna M.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (03) : 363 - 368
  • [8] Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database
    Bradley, Marie C.
    Fahey, Tom
    Cahir, Caitriona
    Bennett, Kathleen
    O'Reilly, Dermot
    Parsons, Carole
    Hughes, Carmel M.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (10) : 1425 - 1433
  • [9] Characteristics of Randomized Controlled Trials Designed for Elderly: A Systematic Review
    Broekhuizen, Karen
    Pothof, Axel
    de Craen, Anton J. M.
    Mooijaart, Simon P.
    [J]. PLOS ONE, 2015, 10 (05):
  • [10] Polypharmacy: Misleading, but manageable
    Bushardt, Reamer L.
    Massey, Emily B.
    Simpson, Temple W.
    Ariail, Jane C.
    Simpson, Kit N.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2008, 3 (02) : 383 - 389